Li Zili Appointed Head of Drug and Device Regulation to Drive Approval Reform

On 26 October 2026, the newly appointed Director of Drug and Medical Device Regulation, Li Zili, said a cross-disciplinary scientific team centred on clinical review would be set up to build a drug regulatory body with comprehensive capability, international trust and an independent strategic position. On the same day, Director of Health Lam Man-kin said he believed Li Zili's extensive international experience and leadership would enable Hong Kong to reform its pharmaceutical approval system. The report did not mention the specific date Li Zili took office or details of his past experience, nor did it explain the composition of the cross-disciplinary scientific team, its establishment timetable or specific reform measures for the drug regulatory body. The current progress is that Li Zili has announced the direction for building the team and the body, and Lam Man-kin has publicly expressed confidence in his leadership of the approval system reform.

Generated by AI from reporting · updated 2 hours ago

There are not enough continuous observations to draw a trend yet.